150 related articles for article (PubMed ID: 14987898)
1. Plea to restore public funding for vaccine development.
Puliyel JM
Lancet; 2004 Feb; 363(9409):659. PubMed ID: 14987898
[No Abstract] [Full Text] [Related]
2. US advisory panel urges government to subsidise vaccine costs. Recommendations would increase vaccination rates and stimulate research and development.
Ault A
Lancet; 2003 Aug; 362(9383):539. PubMed ID: 12932398
[No Abstract] [Full Text] [Related]
3. Medicine. The intangible value of vaccination.
Rappuoli R; Miller HI; Falkow S
Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
[No Abstract] [Full Text] [Related]
4. Determinants of vaccine supply.
Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
[No Abstract] [Full Text] [Related]
5. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
Shen AK; Rodewald LE; Birkhead GS
Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
[TBL] [Abstract][Full Text] [Related]
6. Cash crisis looms for vaccine drive.
Butler D
Nature; 2010 Mar; 464(7287):338. PubMed ID: 20237535
[No Abstract] [Full Text] [Related]
7. Public health. U.S. vaccine supply falls seriously short.
Cohen J
Science; 2002 Mar; 295(5562):1998-2001. PubMed ID: 11896251
[No Abstract] [Full Text] [Related]
8. Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse.
Tyagi V; Singh SK; Sawhney A; Taneja V; Puliyel JM
Pharmacoeconomics; 2003; 21(7):497-9. PubMed ID: 12696989
[No Abstract] [Full Text] [Related]
9. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
10. Vaccine development and deployment: opportunities and challenges in India.
Gupta SS; Nair GB; Arora NK; Ganguly NK
Vaccine; 2013 Apr; 31 Suppl 2():B43-53. PubMed ID: 23598492
[TBL] [Abstract][Full Text] [Related]
11. The fragility of the U.S. vaccine supply.
Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
[No Abstract] [Full Text] [Related]
12. The U.S. vaccine supply.
Schwartz HK
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
[No Abstract] [Full Text] [Related]
13. The U.S. vaccine supply.
Hinman AR
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020
[No Abstract] [Full Text] [Related]
14. Global perspectives on vaccine financing.
Berman S; Giffin RB
Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
[TBL] [Abstract][Full Text] [Related]
15. [Reasons for an injury compensation programme for adverse vaccine-related events in Spain].
Tuells J
Med Clin (Barc); 2013 Jun; 140(12):554-7. PubMed ID: 23540383
[No Abstract] [Full Text] [Related]
16. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
17. Maintaining the vaccine safety net.
Hannan C; Buchanan AD; Monroe J
Pediatrics; 2009 Dec; 124 Suppl 5():S571-2. PubMed ID: 19948593
[No Abstract] [Full Text] [Related]
18. Valuing childhood vaccines.
Davis MM; Kemper AR
J Pediatr; 2003 Sep; 143(3):283-4. PubMed ID: 14517503
[No Abstract] [Full Text] [Related]
19. [Vaccination against hepatitis B in Switzerland: towards a global strategy].
Kammerlander R; Vaudaux B; Bourquin C; Zimmermann HP; Raeber PA
Rev Med Suisse Romande; 1998 Apr; 118(4):335-9. PubMed ID: 9623285
[No Abstract] [Full Text] [Related]
20. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan.
Kane MA
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):2-3. PubMed ID: 12540496
[No Abstract] [Full Text] [Related]
[Next] [New Search]
